已出刊文章

【綜合評述】口服抗癲癇藥用於成人頑固型或極頑固型持續癲癇發作狀態之文獻探討
Literature Review on Oral Anti-Seizure Medication for Adults with Refractory and Super-Refractory Status Epilepticus
口服抗癲癇藥、頑固型持續癲癇發作狀態、極頑固型持續癲癇發作狀態、oral anti-seizure medication, refractory status epilepticus, super-refractory status epilepticus
徐麗珍 Li-Jen Hsu1,* 、蔡玉娟 Yu-Chuan Tsai1 、黃淑萍 Sock-Ping Ng1 、徐雅玫 Ya-Mei Hsu1
1彰化基督教醫院藥學部

摘要
頑固型或極頑固型持續癲癇發作狀態屬於危急重症,需緊急藥物治療,原則上以注射型藥物為優先。然而部分病人可能因病情嚴重複雜、藥物不良反應、禁忌症或資源限制,需考量使用口服劑型的抗癲癇藥,如:clobazam、pregabalin、topiramate、perampanel等。本文透過回顧文獻中口服抗癲癇藥在頑固型或極頑固型持續癲癇發作狀態病人的應用經驗與結果,探討可能影響療效、藥物不良反應的相關因素,期望對此類病人在治療策略中提供更多可供參考的用藥資訊。整體而言,目前口服抗癲癇藥在頑固型或極頑固型持續癲癇發作的文獻證據仍有限,相關研究多為病例報告、病例系列或小型回溯性研究,證據等級與一致性不足。現階段僅建議作為特定情境下的輔助治療選項,無法取代注射型藥物作為主要治療策略,未來仍需更多前瞻性與系統性研究,進一步釐清其療效、安全性及最佳使用時機。
 
ABSTRACT
Refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE) are critical emergencies, which require emergency pharmacological therapy. Injectable drugs are generally preferred. However, in some patients, the use of oral anti-seizure medications (ASMs), such as clobazam, pregabalin, topiramate and perampanel, may need to be considered because of severe and complex clinical conditions, adverse drug reactions, contraindications, or resource-limited settings. We review the application and clinical outcomes of ASMs in patients with RSE and SRSE, and discuss factors that may be associated with efficacy and adverse drug reactions. The aim of this article is to provide these patients with more information on medication use in the treatment strategies. In conclusion, the literature evidence on oral ASMs in RSE and SRSE is still limited. Most studies are case reports, case series, or small retrospective studies with insufficient level of evidence and consistency. At present, it is only recommended as an add-on therapy option in specific situations and cannot replace injectable drugs as the primary treatment. Further prospective and systematic studies are needed to clarify its efficacy, safety, and optimal timing of use.
 
Submitted for publication: 2025.09.18; Accepted for publication: 2026.03.16

操作進行中,請稍候~~~~
×
加载中...

系統通知

不再顯示此通知
×